Samfur Description
Raw Semaglutide Basic Characters
| Product Name: | Semaglutide |
| Lambar CAS: | 910463-68-2 |
| Kwayoyin Formula: | C187H291N45O59 |
| Girman kwayoyin halitta: | 4113.58g / mol |
| Shawarwar Melt: | 34-39 ° C |
| Color: | White |
| Ajiye Temp: | Ajiye a 8 ° C-20 ° C, kare kariya daga danshi da haske |
Menene Semaglutide?
Semaglutide shine glucagon-kamar peptide-1 agonist mai karɓa wanda aka yi amfani da shi a cikin mutane masu ciwon sukari na 2 azaman ƙari ga abinci da motsa jiki don haɓaka sarrafa glycemic.Semaglutide shine GLP-1 mimic yana da 94% jerin homology ga ɗan adam GLP-1. Yana iya ɗaure ga mai karɓar GLP-1 kuma yana kunna mai karɓa don rage sukarin jini ta hanyar haɓaka samar da insulin da raguwar ɓoyewar glucagon azaman mai karɓar GLP-1. agonist.Bugu da ƙari, semaglutide na iya yin aiki akan tsarin narkewa ta hanyar jinkirta ɓarna gastrointestinal don haifar da cikawa; akan kwakwalwa ta hanyar hana ci; da kuma kan tsarin jini ta hanyar gyara lalacewar intima da inganta aikin endothelial.
Ta yaya Semaglutide ke aiki?
Semaglutide foda agonist ne na mai karɓar glucagon-kamar peptide-1. Yana haɓaka samar da insulin, hormone wanda ke rage matakan sukari na jini, ta hanyar kwaikwayon tasirin incretin glucagon-kamar peptide-1 (GLP-1) kuma yana bayyana. don tayar da haɓakar ƙwayoyin beta na pancreatic, waɗanda ke da alhakin samar da insulin da saki. Bugu da ƙari, AASraw semaglutide yana da ikon rage yawan samar da glucagon, wani hormone wanda ke motsa glycogenolysis (sakin carbohydrates da aka adana daga hanta) da gluconeogenesis (da halittar sabon glucose) .Yana rage cin abinci ta hanyar danne yunwa da rage narkewar ciki, wanda ke taimakawa wajen rage kiba.Yana hana ci abinci, sha’awar abinci, da adana mai.
Bincike akan Semaglutide
① Gabatarwa
Semaglutide wani magani ne wanda aka samo asali don magance ciwon sukari. Duk da haka, ya sami karbuwa a matsayin maganin asarar nauyi bayan an gano shi don taimakawa mutane su rasa nauyi, ciki har da mai arziki na biyu na duniya, Elon Musk. Kwanan nan, binciken--Semaglutide sau ɗaya-Makowa a cikin Matasa masu Kiba--an buga a cikin New England Jaridar Magunguna (NEJM) ya gano cewa semaglutide na iya taimakawa matasa masu kiba su rage kiba da inganta lafiyar zuciya.
②Mahimmin Bincike
- Matasa masu kiba waɗanda suka ɗauki semaglutide na mako-mako sun ga karuwar 16.1% a cikin ma'aunin jiki (BMI) a cikin gwajin gwaji na duniya na 3a, idan aka kwatanta da karuwar 0.6% a cikin rukunin placebo.
- Semaglutide shine glucagon-kamar peptide 1 (GLP-1) agonist mai karɓa wanda zai iya rage ci, abinci, da yawan kuzari, yana mai da tasiri ga asarar nauyi.
- Wani babban gwaji na asibiti ya nuna cewa semaglutide yana da tasiri mai ban mamaki a matsayin magani na asarar nauyi, tare da rukunin da aka kula da su sun rasa matsakaicin 15.3 kg.
- A cikin Yuni 2021, Hukumar Abinci da Magunguna (FDA) ta amince da tallan na semaglutide (Semaglutide), magani mai asarar nauyi tare da sunan kasuwanci na Wegovy.
- Wani binciken da aka yi kwanan nan ya gano cewa semaglutide ya wuce placebo dangane da asarar nauyi da inganta abubuwan haɗari na cardiometabolic a cikin samari masu kiba.
- Bayan shan semaglutide, abubuwan haɗari na zuciya da jijiyoyin jini kamar kewayen kugu, ma'aunin glucose na jini HbA1c, jimlar cholesterol, ƙarancin ƙima da ƙarancin ƙarancin lipoprotein cholesterol, triglycerides, da triglycerides sun inganta.
- Ƙungiyar semaglutide ta zarce ƙungiyar placebo akan ingancin rayuwa masu alaƙa da nauyi, saboda yawanci zuwa mafi girman ƙimar ta'aziyya ta jiki.
③Kammalawa
An nuna Semaglutide a matsayin magani mai mahimmanci na asarar nauyi, kuma bincike na baya-bayan nan ya nuna cewa yana iya zama da amfani ga matasa masu kiba.Yayin da magani yana hade da wasu cututtuka na gastrointestinal, an samo shi don inganta abubuwan haɗari na zuciya da jijiyoyin jini da kuma ingancin ingancin. matakan rayuwa.
Tushen Asalin:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997064/
Fa'idodi na Amfani Semaglutide
Semaglutide magani ne mai mahimmanci wanda ke ba da fa'ida ga mutane da yanayin kiwon lafiya daban-daban.Wasu daga cikin mafi yawan yanayi na yau da kullun waɗanda zasu iya amfana daga amfani da AASraw Semaglutide ciki har da Nau'in Ciwon sukari na 2, haɗarin caidiovascular, kiba da Alzheimer.
①Rage Matsayin Glucose na Jini
Semaglutide shine agonist mai karɓa na GLP-1 wanda ke da tasiri wajen rage matakan glucose na jini a cikin mutanen da ke da nau'in ciwon sukari na 2 ta hanyoyi da yawa. Yana ƙarfafa ƙwayar insulin, wanda ke taimakawa wajen motsa glucose daga jini zuwa sel inda za'a iya amfani da shi don makamashi. Har ila yau, Semaglutide yana hana ƙwayar glucagon, wanda ke rage samar da glucose ta hanta. Bugu da ƙari, yana rage yawan zubar da ciki, wanda ke rage yawan glucose ya shiga cikin jini bayan cin abinci.
A cikin gwaje-gwajen asibiti, an nuna semaglutide don rage matakan HbA1c sosai, wanda ke nuna alamar sarrafa glucose na jini na dogon lokaci. gwaji, ya rage matakan HbA1c da 1% idan aka kwatanta da placebo.Semaglutide kuma an nuna yana da tasiri wajen rage matakan glucose na plasma na azumi da kuma balaguron balaguron glucose na postprandial.
②Rage Hatsarin Al'amuran Zuciya
An nuna Semaglutide don rage haɗarin manyan abubuwan da ke faruwa na zuciya da jijiyoyin jini (MACE) irin su mutuwar zuciya da jijiyoyin jini, infarction myocardial marar mutuwa, da bugun jini marar mutuwa a cikin manya da nau'in ciwon sukari na 2 da kuma kafa cututtukan zuciya na zuciya.An lura da wannan fa'ida a cikin SUSTAIN-6 da PIONEER. -6 gwaje-gwaje, wanda ya nuna raguwa mai yawa a cikin MACE tare da maganin semaglutide idan aka kwatanta da placebo. Bugu da ƙari, an nuna Semaglutide don inganta yawan haɗarin cututtukan zuciya kamar hawan jini, bayanin martaba, da alamomi na kumburi a cikin mutanen da ke fama da ciwon sukari na 2. gwajin SUSTAIN-6, semaglutide yana da alaƙa da raguwa mai mahimmanci a cikin karfin jini na systolic da haɓakawa a cikin bayanan lipid, gami da raguwa a cikin jimlar cholesterol, LDL cholesterol, da triglycerides.
③Rage Nauyi
Semaglutide wani wakili ne mai mahimmanci na asarar nauyi, har ma a cikin mutanen da ba tare da ciwon sukari ba.Semaglutide yana aiki ta hanyar rage cin abinci da yawan adadin kuzari, yana haifar da raguwa a cikin nauyin jiki. Wannan yana samuwa ta hanyar tasirinsa akan tsarin juyayi na tsakiya da gastrointestinal tract.Semaglutide yana aiki akan hypothalamus, wanda ke daidaita yunwa da jin dadi, kuma yana rage sha'awar cin abinci ta hanyar ƙara yawan jin dadi. Bugu da ƙari, semaglutide yana rage yawan zubar da ciki, wanda ya tsawaita jin dadi bayan cin abinci kuma yana rage sha'awar cin abinci.
Gwaje-gwaje na asibiti sun nuna amfanin asarar nauyi na semaglutide.A cikin shirin STEP, wanda yayi la'akari da amfani da semaglutide don kula da nauyi a cikin mutanen da ba tare da ciwon sukari ba, semaglutide yana da alaƙa da asarar nauyi idan aka kwatanta da placebo. Matsakaicin kashi 15% na nauyin jikinsu sama da makonni 68, yayin da waɗanda suka karɓi placebo suka rasa kashi 2.4 kawai.
A cikin mutanen da ke da nau'in ciwon sukari na 2, semaglutide na iya haifar da ƙarin fa'idodin asarar nauyi. A cikin gwajin SUSTAIN 7, wanda ya kimanta inganci da amincin semaglutide a cikin mutanen da ke da nau'in ciwon sukari na 2, an danganta semaglutide tare da raguwa mai yawa a cikin nauyin jiki idan aka kwatanta da placebo. .Masu halartan da suka karɓi semaglutide sun rasa matsakaicin 4.6 kg, yayin da waɗanda suka karɓi placebo sun rasa kilogiram 1.2 kawai.
④ Yin Maganin Alamar Cutar Alzheimer
Yawancin bincike na farko sun nuna cewa semaglutide yana da kaddarorin neuroprotective akan amyloid-β plaques a cikin layin salula na mutum neuroblastoma (SH-SY5Y), yana ba da shawarar cewa semaglutide na iya rage alamun cutar Alzheimer. A cewar sanarwar Novo Nordisk, alamun semaglutide allunan don cutar Alzheimer (AD) yana cikin matakin asibiti. Gwajin gwaji na Phase III na duniya guda biyu, EVOKE da EVOKE da ƙari, ana ci gaba da ɗauka, kuma ana sa ran za a ɗauki masu aikin sa kai kusan 3,700. A cikin wannan binciken. , idan aka kwatanta da placebo, kimanta fifikon allunan semaglutide akan aikin fahimi a cikin abubuwan da ke da raunin fahimi (MCI) ko ƙarancin lalata da AD ya haifar.
Tsare-tsare: Yana da mahimmanci don siyan semaglutide daga tushe masu daraja, in ba haka ba, ba za ku iya samun mafi kyawun ingancin semaglutide ba.A matsayin ƙwararrun masana'antar semaglutide kuma mai siyarwa, AASraw yana nufin samar da semaglutide mai tsabta a duk duniya.Idan kuna da buƙatu, AASraw's semaglutide babban zaɓi ne. na ka.
Tasirin Side na Semaglutide?
Semaglutide, kamar kowane magani, na iya haifar da illa.
①Illalai na yau da kullun sun haɗa da:
- Tashin zuciya
- Vomiting
- zawo
- Abun ciki na ciki
- Rashin ci
- maƙarƙashiya
- ciwon kai
- gajiya
- Dizziness
②Ƙasashen gama gari amma mafi munin illolin na iya haɗawa da:
- Pancreatitis
- Hypoglycemia (ƙananan ciwon sukari)
- Raunin raunin koda
- Matsalolin retinopathy na ciwon sukari
- Gallbladder cuta
- Allergic halayen
- Ciwon thyroid
Bayanan kula: Tsawon lokaci na illa na semaglutide na iya bambanta dangane da mutum da kuma tsananin illa. tashin zuciya, zawo, amai, maƙarƙashiya, da ciwon kai yawanci warware a cikin 'yan kwanaki zuwa mako guda.Idan ka fuskanci wani sabon abu ko mai tsanani illa yayin shan semaglutide, je likita da sauri.Bugu da ƙari, siyan semaglutide tare da high quality daga abin dogara maroki, kamar AASraw, yana da mahimmanci.
Sashi da Gudanar da Semaglutide don Magana
Matsakaicin sashi da gudanarwa na semaglutide na iya bambanta dangane da alamar amfani. Ga wasu jagororin gabaɗaya:
① Alamun: Nau'in ciwon sukari na 2
· Allurar subcutaneous
Makon 1-4: 0.25 mg / mako
Makon 5 kuma gaba: 0.5 mg / mako
√ Idan an buƙata, bayan akalla makonni 4 akan kashi na 0.5-MG, ƙara zuwa 1 MG subcutaneously sau ɗaya a mako.
√ Idan an buƙata, bayan akalla makonni 4 akan kashi na 1-MG, ƙara zuwa 2 MG subcutaneously sau ɗaya a mako; kada ku wuce 2 mg / mako.
· Tablet na baka
Ranar 1-30: 3 mg / rana
Ranar 31 kuma gaba: 7 mg / rana
√ Idan an buƙata, bayan akalla kwanaki 30 akan kashi na 7-MG, ƙara zuwa 14 MG na baki sau ɗaya kowace rana.
√ Lura: Kada a ɗauki allunan 7-mg guda biyu don cimma kashi na 14-MG
② Nuni: Gudanar da Nauyi na yau da kullun
· Allurar subcutaneous
Makon 1-4: 0.25 mg / mako
Makon 5-8: 0.5 mg / mako
Makon 9-12: 1 mg / mako
Makon 13-16: 1.7 mg / mako
Makon 17 da gaba: 2.4 mg / mako (kashin kulawa)
√ Fara tare da ƙananan kashi kuma a hankali haɓaka zuwa adadin kulawa don rage mummunan halayen ciki.
√ Idan ba za a iya jure wa kashi yayin haɓakawa ba, la'akari da jinkirta haɓaka kashi na makonni 4.
√ Idan ba za a iya jure wa adadin kulawa na 2.4 MG sau ɗaya a mako ba, na iya raguwa na ɗan lokaci zuwa 1.7 MG sau ɗaya a mako don iyakar makonni 4; bayan makonni 4, karuwa a baya don kulawa 2.4 MG sau ɗaya a mako; daina idan ba a yarda ba bayan ƙoƙari na biyu.
√ Lura: Matsakaicin sashi da gudanarwa na semaglutide na iya bambanta dangane da alamun amfani.Bi umarnin likitan ku ko kuma kamar yadda aka nuna akan lakabin magani.Bugu da ƙari, yi ƙoƙarin siyan semaglutide mai tsabta don cimma mafi kyawun inganci.
Inda zan saya Semaglutide?
Semaglutide, magani da ake nema sosai don maganin ciwon sukari na 2, ya zama sananne a tsakanin marasa lafiya da ke neman ingantattun hanyoyin magance yanayin su.A sakamakon haka, kasuwannin kan layi sun fito a matsayin dandamali mai dacewa don mutane su sayi semaglutide akan layi. dandamali na dijital suna ba abokan ciniki damar kwatanta farashin, karanta bita, da samun dama ga zaɓuɓɓuka masu yawa don dacewa da bukatunsu. Duk da haka, yana da mahimmanci ga abokan ciniki su yi taka tsantsan yayin siyan semaglutide akan layi, saboda samfuran jabu ko ƙarancin inganci na iya yuwuwa. Ta hanyar gudanar da bincike mai zurfi da kuma zaɓar mai siye mai daraja kuma ƙwararren mai siyarwa, daidaikun mutane za su iya amincewa da siyan semaglutide akan layi kuma su sarrafa yadda ya kamata cikin ciwon sukari cikin sauƙi.
AASraw da nufin masana'anta abd samar da matsakaicin sinadarai da kayan aikin magunguna masu aiki (APIs), amintaccen mai ba da sabis ne na semaglutide mai inganci da sauran samfuran da ke da alaƙa. Ƙaddamar da ƙwaƙƙwaran ingancin kulawa da bin ka'idodin masana'antu yana tabbatar da cewa abokan ciniki suna karɓar mafi kyawun samfuran kawai don samfuran su. kiwon lafiya da jin dadi.Ta hanyar siyayya a AASraw, daidaikun mutanen da ke neman semaglutide na iya jin daɗin dacewa, amintaccen, da ingantaccen ƙwarewar siye, duk yayin da suke cin gajiyar iliminsu da ƙwarewa a fagen.
Rahoton Gwajin Semaglutide-HNMR
Menene HNMR kuma Menene Bakan HNMR ke gaya muku?H Nuclear Magnetic Resonance (NMR) spectroscopy dabara ce ta nazarin sinadarai da ake amfani da ita wajen sarrafa inganci da bincike don tantance abun ciki da tsarkin samfurin da kuma tsarinsa na ƙwayoyin cuta.Alal misali, NMR na iya yin nazarin gaurayawan da ke ɗauke da sanannun mahadi. Don abubuwan da ba a sani ba, NMR za a iya amfani da su don daidaitawa da ɗakunan karatu na bakan ko kuma don ƙaddamar da ainihin tsarin kai tsaye. Da zarar an san ainihin tsarin, ana iya amfani da NMR don ƙayyade daidaituwar kwayoyin halitta. a cikin bayani da kuma nazarin kaddarorin jiki a matakin kwayoyin halitta kamar musanya mai daidaituwa, canje-canjen lokaci, narkewa, da yadawa.
Semaglutide-COA
Semaglutide (910463-68-2) - COA
Yadda ake siyan Semaglutide daga AASraw?
❶Don tuntuɓar mu ta tsarin binciken imel ɗin mu, ko kuma ku bar mana lambar ku ta whatsapp, wakilin sabis na abokin ciniki (CSR) zai tuntuɓar ku cikin awanni 12.
❷Don samar mana da adadin ku da adireshin ku.
❸CSR ɗin mu zai ba ku fa'ida, lokacin biyan kuɗi, lambar bin diddigi, hanyoyin bayarwa da ƙididdigar ranar isowa (ETA).
❹An gama biyan kuɗi kuma za a aika da kayan a cikin awanni 12.
❺Kayan da aka karɓa kuma a ba da sharhi.
Marubucin wannan labarin:
Dr. Monique Hong ya sauke karatu daga Kwalejin Kimiyya ta Burtaniya ta London Faculty of Medicine
Mawallafin Jaridar Kimiyya:
1. CC Carson
Sashen tiyata, Sashen Urology, Jami'ar North Carolina, Chapel Hill, NC,
2. I. Eardley
Asibitin Jami'ar St. James, Leeds, UK,
3. DJ Walker
Eli Lilly and Company, Indianapolis, IN, Amurka
4. WH Cordell
Eli Lilly and Company, Indianapolis, IN, Amurka
Babu wata hanya da wannan likita/masanin kimiyyar ya yarda ko ba da shawarar siyan, siyarwa, ko amfani da wannan samfur saboda kowane dalili. Aasraw ba shi da wata alaƙa ko alaƙa, a fayyace ko akasin haka, tare da wannan likitan. Manufar ambaton wannan likita shine yarda, yarda da kuma yaba da cikakken bincike da ayyukan ci gaba da masana kimiyyar da ke aiki akan wannan abu suka yi.
reference:
[1] Ghusn W,De la Rosa A,Sacoto D,Cifuentes L,Campos A,Feris F,Hurtado MD,Acosta A.Sakamakon Rage Nauyi Haɗe da Jiyya na Semaglutide ga Marasa lafiya masu Kiba ko Kiba.JAMA Netw Bude.2022 Sep 1;5(9):e2231982.
[2] Wilding JPH,Batterham RL,Davies M,Van Gaal LF,Kandler K,Konakli K,Lingvay I,McGowan BM,Oral TK,Rosenstock J,Wadden TA,Wharton S,Yokote K,Kushner RF; MATAKI NA 1 Rukunin Nazari.Sake dawo da nauyi da tasirin cardiometabolic bayan cirewar semaglutide: Tsawaita gwaji na STEP 1.Ciwon Ciwon sukari Metab.2022 Aug;24(8):1553-1564.
[3] Garvey WT,Batterham RL,Bhatta M,Buscemi S,Christensen LN,Frias JP,Jódar E,Kandler K,Rigas G,Wadden TA,Wharton S; Mataki na 5 Rukunin Nazarin.Tsarin shekaru biyu na semaglutide a cikin manya tare da kiba ko kiba: gwaji na STEP 5.Nat Med.2022 Oct; 28 (10): 2083-2091.
[4] Knudsen LB,Lau J.Ganowa da Ci gaban Liraglutide da Semaglutide.Front Endocrinol (Lausanne).2019 Apr 12;10:155.
[5] Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, a Abating Obesity, Non-Alcoholic Steatohepatitis da Neurodegenerative cututtuka: A Narrative Review.Pharm Res.2022 Jun;39 ): 6-1233.
